Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

58% of Physicians Support FDA Move to Pull Breast Cancer Indication from Avastin

February 4, 2011 By Bio-Medicine.Org

CAMBRIDGE, Mass., Feb. 4, 2011 /PRNewswire/ — Sermo (http://www.sermo.com), the world’s
largest online community for physicians, announced the publication
of a free Sermo Report about how physicians are reacting to the FDA
decision to rescind the indication for Avastin (bevacizumab) in the
treatment of breast cancer.  The new report titled “Should
Avastin (bevacizumab) Keep its Breast Cancer Indication?”

reveals how physicians are using Avastin and which therapeutic
agents they will switch to for clinical presentations.

58% of physician respondents support the FDA’s move to pull the
breast cancer indication from Avastin. However, 50% of respondents
also believe that Avastin has increased the quality of life for
breast cancer patients.

Physicians provided commentary on both sides of the debate. Some
believe that the progression free survival benefit previously shown
for Avastin is meaningful.  According to one oncologist on
Sermo, “…if folks can get ‘caught up’ on the survival endpoint by
being able to take Avastin at the time of progression, how can one
possibly prove a survival advantage overall.” Another oncologist
commented, “This is a shame, but we are going to do what the payers
let us do.”

Therapeutic agents listed by physicians that will be used
instead of Avastin in the treatment of breast cancer include, but
are not limited to Resveratrol, Abraxane (paclitaxel), Taxotere
(docetaxel), Gemzar (gemcitabine), Xeloda (capecitabine), Abraxane
(paclitaxel), Taxol (paclitaxel), Navelbine (Vinorelbine) and
Ixempra (ixabepilone).

Many of the respondents also participated in an online
discussion regarding the original Avastin study. The full report
includes:

  • Overview of FDA decision
  • Report methodology
  • Key findings
  • Discussion highlights
  • Changes in physici

    ‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech